Vanguard Capital Management
ICCC icon

Vanguard Capital Management’s ImmuCell ICCC Stock Holding History

Vanguard Capital Management’s Portfolio ICCC Stock Details ICCC Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$2.69M Buy
268,130
+7,803
+3% +$68.9K ﹤0.01% 3319
2026
Q1 		$1.65M Buy
+260,327
New +$1.67M ﹤0.01% 3425

Other funds holding ICCC

Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return
CAM
Cresset Asset Management Chicago, Illinois $27.6B AUM 31.92% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return
BL
Bleichroeder LP New York $559M AUM 83.7% 1-Year Est. Return
S
Steadtrust Allen, Texas $198M AUM 99.37% 1-Year Est. Return
MFIM
Mesirow Financial Investment Management Chicago, Illinois $6.37B AUM 23.22% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $875B AUM 40.91% 1-Year Est. Return
Vanguard Fiduciary Trust
Vanguard Fiduciary Trust Malvern, Pennsylvania $454B AUM

Vanguard Capital Management's ICCC Position: Q2 2026 in Review

Vanguard Capital Management increased its ImmuCell (ICCC) stake by 3% in Q2 2026, buying an estimated $68.9K and bringing the position to 268,130 shares worth $2.69M. The position accounts for ﹤0.01% of the portfolio, ranked #3319.

Vanguard Capital Management first reported a position in ICCC in Q1 2026 and has held it in 2 quarters since. 30 funds tracked by Wall St. Rank hold ICCC as of Q2 2026.

  • Vanguard Capital Management held 268,130 shares of ImmuCell worth $2.69M as of Q2 2026.
  • Vanguard Capital Management bought 7,803 ImmuCell shares in Q2 2026, an estimated $68.9K.
  • ImmuCell made up ﹤0.01% of Vanguard Capital Management's portfolio in Q2 2026, its #3319 holding.
  • Vanguard Capital Management first reported a position in ImmuCell in Q1 2026 and has held it in 2 quarters since.
  • 30 funds tracked by Wall St. Rank held ImmuCell as of Q2 2026.

Based on Vanguard Capital Management's 13F filing for Q2 2026, filed 13 Aug 2026.